Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. Needham, MA
Xenon Pharmaceuticals is a neuroscience‑focused biopharmaceutical company dedicated to drug discovery and clinical development. About the Role Senior Manager/Associate Director, Commercial & Medical Information Systems. The role partners with Commercial and Medical leaders to drive adoption and operate IT systems, including the Veeva suite, Commercial Data Warehouse and other key platforms. Based in Boston, MA (Needham office) with hybrid work (two onsite days per week). Reports to the Director, Commercial & Medical Information Systems. Responsibilities Partner with stakeholders and vendors to build new solutions supporting the Commercial and Medical functions, including system integrations. Author, review, and approve SDLC deliverables; coordinate assurance and testing activities. Develop and approve procedures defining system administration activities. Collaborate with the Architecture Review Board to ensure consistent system design. Manage day‑to‑day operations...

Xenon Pharmaceuticals Inc. Boston, MA
Overview Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3,...